Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 70.6 Cr.
- Current Price ₹ 132
- High / Low ₹ 310 / 122
- Stock P/E 23.0
- Book Value ₹ 56.3
- Dividend Yield 0.00 %
- ROCE 18.0 %
- ROE 14.2 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|
| 8.03 | 18.96 | 27.64 | 37.33 | |
| 7.09 | 16.59 | 23.39 | 32.79 | |
| Operating Profit | 0.94 | 2.37 | 4.25 | 4.54 |
| OPM % | 11.71% | 12.50% | 15.38% | 12.16% |
| 0.01 | 0.03 | 0.08 | 0.08 | |
| Interest | 0.00 | 0.09 | 0.18 | 0.50 |
| Depreciation | 0.00 | 0.01 | 0.02 | 0.03 |
| Profit before tax | 0.95 | 2.30 | 4.13 | 4.09 |
| Tax % | 26.32% | 26.09% | 26.15% | |
| 0.70 | 1.70 | 3.04 | 3.07 | |
| EPS in Rs | 2.03 | 3.47 | 6.12 | 5.89 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 70% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 |
| Reserves | 13.44 | 19.60 | 24.77 |
| 1.60 | 3.26 | 6.79 | |
| 0.94 | 3.02 | 6.76 | |
| Total Liabilities | 20.88 | 30.85 | 43.67 |
| 0.05 | 1.65 | 1.73 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.43 | 0.44 | 0.44 |
| 20.40 | 28.76 | 41.50 | |
| Total Assets | 20.88 | 30.85 | 43.67 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -0.79 | 1.80 | ||
| -4.55 | -11.07 | ||
| 13.10 | 2.89 | ||
| Net Cash Flow | 7.77 | -6.39 | |
| Free Cash Flow | -0.82 | 0.18 | |
| CFO/OP | -33% | 58% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 90.48 | 117.79 | |
| Inventory Days | 6.27 | 53.66 | |
| Days Payable | 0.46 | 22.43 | |
| Cash Conversion Cycle | 96.29 | 149.02 | |
| Working Capital Days | 118.78 | 100.63 | |
| ROCE % | 18.04% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (Number of States/Regions) Number |
|
|
| Net Capital Turnover Ratio Ratio |
||
| Number of Permanent Employees Number |
||
| US FDA Approved Products Number |
||
| E-Commerce Distribution Partnerships (Zepto/Blinkit) Number |
||
| Number of New Products Launched (Annual) Number |
||
Extracted by Screener AI
Documents
Announcements
-
Non-Applicability Of The Submission Of Annual Secretarial Compliance Report Under Regulation 24A(2) Of SEBI (LODR) Regulation, 2015.
1d - Royal Sense says FY26 Annual Secretarial Compliance Report is not applicable under SME exemption.
-
Board Meeting Intimation for Intimation Of The Board Meeting Pursuant To The Regulation 29 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015.
20 May - Board meets 25 May 2026 to approve FY26 audited results and revise ESOP 2024.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
20 May - Royal Sense launched seven pharma products and one blood pressure monitor on 20 May 2026.
-
Appointment of Company Secretary and Compliance Officer
19 May - Board appointed Prachi Agnihotri as Company Secretary and Compliance Officer effective 19 May 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 19Th May, 2026 Pursuant To The Regulation 30 Of The SEBI (LODR) Regulations, 2015.
19 May - Royal Sense appointed Prachi Agnihotri as Company Secretary and Compliance Officer effective 19 May 2026.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.